{"id":"NCT02604342","sponsor":"Hoffmann-La Roche","briefTitle":"Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib","officialTitle":"Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy and Crizotinib","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-03","primaryCompletion":"2017-01-26","completion":"2018-08-13","firstPosted":"2015-11-13","resultsPosted":"2018-02-26","lastUpdate":"2019-10-29"},"enrollment":119,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Alectinib","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":["Taxotere®"]},{"type":"DRUG","name":"Pemetrexed","otherNames":["Alimta®"]}],"arms":[{"label":"Alectinib","type":"EXPERIMENTAL"},{"label":"Premetrexed/Docetaxel","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized active-controlled multicenter Phase III open-label study will evaluate and compare between treatment groups the efficacy of alectinib versus chemotherapy in participants with ALK-positive advanced NSCLC who were previously treated with chemotherapy and crizotinib, as measured by investigator-assessed progression-free survival (PFS) and to evaluate and compare between treatment groups the central nervous system (CNS) objective response rate (C-ORR) in participants with measurable CNS metastases at baseline, as assessed by an Independent Review Committee (IRC).","primaryOutcome":{"measure":"Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator","timeFrame":"Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)","effectByArm":[{"arm":"Experimental: Alectinib","deltaMin":10.9,"sd":null},{"arm":"Active Comparator: Premetrexed/Docetaxel","deltaMin":1.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":3},"locations":{"siteCount":54,"countries":["Belgium","Bulgaria","France","Germany","Hong Kong","Hungary","Italy","Norway","Poland","Portugal","Russia","Slovakia","South Korea","Spain","Turkey (Türkiye)"]},"refs":{"pmids":["39661917","29668860"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":77},"commonTop":["Constipation","Anaemia","Asthenia","Myalgia","Fatigue"]}}